Drug of Abuse Testing Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2025

Description

The global drug abuse testing market was valued at USD 7.6 billion in 2024 and is expected to grow steadily, reaching USD 11.3 billion by 2032. This represents a CAGR of 5.1% during the forecast period from 2025 to 2032. The increasing prevalence of substance abuse, rising workplace drug testing mandates, and growing awareness about drug abuse consequences are key factors driving market growth.

Technological advancements in testing methods and the expanding use of rapid and point-of-care drug testing kits are further enhancing market dynamics. Additionally, stringent government regulations and policies promoting drug abuse prevention across various sectors are supporting increased adoption of drug abuse testing solutions globally.

Key Insights

The drug abuse testing market size stood at USD 7.6 billion in 2024 and is projected to reach USD 11.3 billion by 2032, growing at a CAGR of 5.1%.

Urine drug testing remains the most widely used method due to its reliability and cost-effectiveness.

Hair and saliva testing segments are gaining popularity for their non-invasive nature and longer detection windows.

North America dominates the market, driven by strict workplace drug testing regulations and high healthcare spending.

Asia-Pacific is anticipated to register the fastest growth, supported by increasing substance abuse awareness and expanding healthcare infrastructure.

Rapid test kits and point-of-care devices are emerging as preferred choices for on-site drug screening.

Key players such as Abbott Laboratories, Thermo Fisher Scientific, and Quest Diagnostics are investing in product innovation and expanding their global reach.

Growing government initiatives and funding for drug abuse prevention programs are propelling market growth.

Increasing demand for workplace drug testing across various industries, including transportation, construction, and manufacturing, is boosting market adoption.

Enhanced sensitivity and specificity of new testing technologies are improving accuracy and reducing false positives.

Product Code: 10038

Chapter 1. Research Scope

1.1. Research Objectives
1.2. Market Definition
1.3. Analysis Period
1.4. Market Size Breakdown by Segments
- 1.4.1. Market Size Breakdown, by Product
- 1.4.2. Market Size Breakdown, by Sample Type
- 1.4.3. Market Size Breakdown, by End User
- 1.4.4. Market Size Breakdown, by Drug Type
- 1.4.5. Market Size Breakdown, by Region
- 1.4.6. Market Size Breakdown, by Country
1.5. Market Data Reporting Unit
- 1.5.1. Revenue
1.6. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence Database
2.2. Primary Research
2.3. Market Size Estimation
2.4. Data Triangulation
2.5. Currency Conversion Rates
2.6. Assumptions for the Study
2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

5.1. Industry Background
5.2. Market Dynamics
- 5.2.1. Trends
- 5.2.2. Drivers
- 5.2.3. Restraints/Challenges
- 5.2.4. Emerging Economies and Key Opportunities
- 5.2.5. Impact Analysis of Drivers/Restraints
5.3. Impact of COVID-19
5.4. Sociopolitical Impact
5.5. Porter's Five Forces Analysis
- 5.5.1. Bargaining Power of Buyers
- 5.5.2. Bargaining Power of Suppliers
- 5.5.3. Threat of New Entrants
- 5.5.4. Intensity of Rivalry
- 5.5.5. Threat of Substitutes
5.6. Innovation and Technology Trends
5.7. Economic and Regulatory Impact
5.8. Market Entry Strategies

Chapter 6. Competitive Landscape

6.1. List of Market Players and their Offerings
6.2. Market Share of Key Players (2024)
- 6.2.1. Global
- 6.2.2. North America
- 6.2.3. Europe
- 6.2.4. Asia Pacific
- 6.2.5. Latin America
- 6.2.6. Middle East and Africa
6.3. Competitive Benchmarking of Key Players
6.4. Product Benchmarking of Key Players
6.5. Recent Strategic Developments by Key Players
6.6. Company Leadership Matrix

Chapter 7. Global Market

7.1. Overview
7.2. Market Revenue, by Product (2019-2032)
7.3. Market Revenue, by Sample Type (2019-2032)
7.4. Market Revenue, by End User (2019-2032)
7.5. Market Revenue, by Drug Type (2019-2032)
7.6. Market Revenue, by Region (2019-2032)

Chapter 8. North America Market

8.1. Overview
8.2. Market Revenue, by Product (2019-2032)
8.3. Market Revenue, by Sample Type (2019-2032)
8.4. Market Revenue, by End User (2019-2032)
8.5. Market Revenue, by Drug Type (2019-2032)
8.6. Market Revenue, by Country (2019-2032)

Chapter 9. Europe Market

9.1. Overview
9.2. Market Revenue, by Product (2019-2032)
9.3. Market Revenue, by Sample Type (2019-2032)
9.4. Market Revenue, by End User (2019-2032)
9.5. Market Revenue, by Drug Type (2019-2032)
9.6. Market Revenue, by Country (2019-2032)

Chapter 10. Asia Pacific Market

10.1. Overview
10.2. Market Revenue, by Product (2019-2032)
10.3. Market Revenue, by Sample Type (2019-2032)
10.4. Market Revenue, by End User (2019-2032)
10.5. Market Revenue, by Drug Type (2019-2032)
10.6. Market Revenue, by Country (2019-2032)

Chapter 11. Latin America Market

11.1. Overview
11.2. Market Revenue, by Product (2019-2032)
11.3. Market Revenue, by Sample Type (2019-2032)
11.4. Market Revenue, by End User (2019-2032)
11.5. Market Revenue, by Drug Type (2019-2032)
11.6. Market Revenue, by Country (2019-2032)

Chapter 12. Middle East and Africa Market

12.1. Overview
12.2. Market Revenue, by Product (2019-2032)
12.3. Market Revenue, by Sample Type (2019-2032)
12.4. Market Revenue, by End User (2019-2032)
12.5. Market Revenue, by Drug Type (2019-2032)
12.6. Market Revenue, by Country (2019-2032)

Chapter 13. U.S. Market

13.1. Overview
13.2. Economic Indicators
13.3. Demographics and Population Insights
13.4. Regional Hotspots
13.5. Growth Drivers
13.6. Challenges and Barriers
13.7. Competitive Strategies
13.8. Emerging Players
13.9. Import/Export Policies
13.10. Compliance Requirements
13.11. Emerging Investment Areas
13.12. Major Ongoing Projects
13.13. Market Size and Forecast
- 13.13.1. Market Revenue, by Product (2019-2032)
- 13.13.2. Market Revenue, by Sample Type (2019-2032)
- 13.13.3. Market Revenue, by End User (2019-2032)
- 13.13.4. Market Revenue, by Drug Type (2019-2032)

Chapter 14. Canada Market

14.1. Overview
14.2. Economic Indicators
14.3. Demographics and Population Insights
14.4. Regional Hotspots
14.5. Growth Drivers
14.6. Challenges and Barriers
14.7. Competitive Strategies
14.8. Emerging Players
14.9. Import/Export Policies
14.10. Compliance Requirements
14.11. Emerging Investment Areas
14.12. Major Ongoing Projects
14.13. Market Size and Forecast
- 14.13.1. Market Revenue, by Product (2019-2032)
- 14.13.2. Market Revenue, by Sample Type (2019-2032)
- 14.13.3. Market Revenue, by End User (2019-2032)
- 14.13.4. Market Revenue, by Drug Type (2019-2032)

Chapter 15. Germany Market

15.1. Overview
15.2. Economic Indicators
15.3. Demographics and Population Insights
15.4. Regional Hotspots
15.5. Growth Drivers
15.6. Challenges and Barriers
15.7. Competitive Strategies
15.8. Emerging Players
15.9. Import/Export Policies
15.10. Compliance Requirements
15.11. Emerging Investment Areas
15.12. Major Ongoing Projects
15.13. Market Size and Forecast
- 15.13.1. Market Revenue, by Product (2019-2032)
- 15.13.2. Market Revenue, by Sample Type (2019-2032)
- 15.13.3. Market Revenue, by End User (2019-2032)
- 15.13.4. Market Revenue, by Drug Type (2019-2032)

Chapter 16. U.K. Market

16.1. Overview
16.2. Economic Indicators
16.3. Demographics and Population Insights
16.4. Regional Hotspots
16.5. Growth Drivers
16.6. Challenges and Barriers
16.7. Competitive Strategies
16.8. Emerging Players
16.9. Import/Export Policies
16.10. Compliance Requirements
16.11. Emerging Investment Areas
16.12. Major Ongoing Projects
16.13. Market Size and Forecast
- 16.13.1. Market Revenue, by Product (2019-2032)
- 16.13.2. Market Revenue, by Sample Type (2019-2032)
- 16.13.3. Market Revenue, by End User (2019-2032)
- 16.13.4. Market Revenue, by Drug Type (2019-2032)

Chapter 17. Spain Market

17.1. Overview
17.2. Economic Indicators
17.3. Demographics and Population Insights
17.4. Regional Hotspots
17.5. Growth Drivers
17.6. Challenges and Barriers
17.7. Competitive Strategies
17.8. Emerging Players
17.9. Import/Export Policies
17.10. Compliance Requirements
17.11. Emerging Investment Areas
17.12. Major Ongoing Projects
17.13. Market Size and Forecast
- 17.13.1. Market Revenue, by Product (2019-2032)
- 17.13.2. Market Revenue, by Sample Type (2019-2032)
- 17.13.3. Market Revenue, by End User (2019-2032)
- 17.13.4. Market Revenue, by Drug Type (2019-2032)

Chapter 18. Italy Market

18.1. Overview
18.2. Economic Indicators
18.3. Demographics and Population Insights
18.4. Regional Hotspots
18.5. Growth Drivers
18.6. Challenges and Barriers
18.7. Competitive Strategies
18.8. Emerging Players
18.9. Import/Export Policies
18.10. Compliance Requirements
18.11. Emerging Investment Areas
18.12. Major Ongoing Projects
18.13. Market Size and Forecast
- 18.13.1. Market Revenue, by Product (2019-2032)
- 18.13.2. Market Revenue, by Sample Type (2019-2032)
- 18.13.3. Market Revenue, by End User (2019-2032)
- 18.13.4. Market Revenue, by Drug Type (2019-2032)

Chapter 19. France Market

19.1. Overview
19.2. Economic Indicators
19.3. Demographics and Population Insights
19.4. Regional Hotspots
19.5. Growth Drivers
19.6. Challenges and Barriers
19.7. Competitive Strategies
19.8. Emerging Players
19.9. Import/Export Policies
19.10. Compliance Requirements
19.11. Emerging Investment Areas
19.12. Major Ongoing Projects
19.13. Market Size and Forecast
- 19.13.1. Market Revenue, by Product (2019-2032)
- 19.13.2. Market Revenue, by Sample Type (2019-2032)
- 19.13.3. Market Revenue, by End User (2019-2032)
- 19.13.4. Market Revenue, by Drug Type (2019-2032)

Chapter 20. China Market

20.1. Overview
20.2. Economic Indicators
20.3. Demographics and Population Insights
20.4. Regional Hotspots
20.5. Growth Drivers
20.6. Challenges and Barriers
20.7. Competitive Strategies
20.8. Emerging Players
20.9. Import/Export Policies
20.10. Compliance Requirements
20.11. Emerging Investment Areas
20.12. Major Ongoing Projects
20.13. Market Size and Forecast
- 20.13.1. Market Revenue, by Product (2019-2032)
- 20.13.2. Market Revenue, by Sample Type (2019-2032)
- 20.13.3. Market Revenue, by End User (2019-2032)
- 20.13.4. Market Revenue, by Drug Type (2019-2032)

Chapter 21. India Market

21.1. Overview
21.2. Economic Indicators
21.3. Demographics and Population Insights
21.4. Regional Hotspots
21.5. Growth Drivers
21.6. Challenges and Barriers
21.7. Competitive Strategies
21.8. Emerging Players
21.9. Import/Export Policies
21.10. Compliance Requirements
21.11. Emerging Investment Areas
21.12. Major Ongoing Projects
21.13. Market Size and Forecast
- 21.13.1. Market Revenue, by Product (2019-2032)
- 21.13.2. Market Revenue, by Sample Type (2019-2032)
- 21.13.3. Market Revenue, by End User (2019-2032)
- 21.13.4. Market Revenue, by Drug Type (2019-2032)

Chapter 22. South Korea Market

22.1. Overview
22.2. Economic Indicators
22.3. Demographics and Population Insights
22.4. Regional Hotspots
22.5. Growth Drivers
22.6. Challenges and Barriers
22.7. Competitive Strategies
22.8. Emerging Players
22.9. Import/Export Policies
22.10. Compliance Requirements
22.11. Emerging Investment Areas
22.12. Major Ongoing Projects
22.13. Market Size and Forecast
- 22.13.1. Market Revenue, by Product (2019-2032)
- 22.13.2. Market Revenue, by Sample Type (2019-2032)
- 22.13.3. Market Revenue, by End User (2019-2032)
- 22.13.4. Market Revenue, by Drug Type (2019-2032)

Chapter 23. Japan Market

23.1. Overview
23.2. Economic Indicators
23.3. Demographics and Population Insights
23.4. Regional Hotspots
23.5. Growth Drivers
23.6. Challenges and Barriers
23.7. Competitive Strategies
23.8. Emerging Players
23.9. Import/Export Policies
23.10. Compliance Requirements
23.11. Emerging Investment Areas
23.12. Major Ongoing Projects
23.13. Market Size and Forecast
- 23.13.1. Market Revenue, by Product (2019-2032)
- 23.13.2. Market Revenue, by Sample Type (2019-2032)
- 23.13.3. Market Revenue, by End User (2019-2032)
- 23.13.4. Market Revenue, by Drug Type (2019-2032)

Chapter 24. Australia Market

24.1. Overview
24.2. Economic Indicators
24.3. Demographics and Population Insights
24.4. Regional Hotspots
24.5. Growth Drivers
24.6. Challenges and Barriers
24.7. Competitive Strategies
24.8. Emerging Players
24.9. Import/Export Policies
24.10. Compliance Requirements
24.11. Emerging Investment Areas
24.12. Major Ongoing Projects
24.13. Market Size and Forecast
- 24.13.1. Market Revenue, by Product (2019-2032)
- 24.13.2. Market Revenue, by Sample Type (2019-2032)
- 24.13.3. Market Revenue, by End User (2019-2032)
- 24.13.4. Market Revenue, by Drug Type (2019-2032)

Chapter 25. Brazil Market

25.1. Overview
25.2. Economic Indicators
25.3. Demographics and Population Insights
25.4. Regional Hotspots
25.5. Growth Drivers
25.6. Challenges and Barriers
25.7. Competitive Strategies
25.8. Emerging Players
25.9. Import/Export Policies
25.10. Compliance Requirements
25.11. Emerging Investment Areas
25.12. Major Ongoing Projects
25.13. Market Size and Forecast
- 25.13.1. Market Revenue, by Product (2019-2032)
- 25.13.2. Market Revenue, by Sample Type (2019-2032)
- 25.13.3. Market Revenue, by End User (2019-2032)
- 25.13.4. Market Revenue, by Drug Type (2019-2032)

Chapter 26. Mexico Market

26.1. Overview
26.2. Economic Indicators
26.3. Demographics and Population Insights
26.4. Regional Hotspots
26.5. Growth Drivers
26.6. Challenges and Barriers
26.7. Competitive Strategies
26.8. Emerging Players
26.9. Import/Export Policies
26.10. Compliance Requirements
26.11. Emerging Investment Areas
26.12. Major Ongoing Projects
26.13. Market Size and Forecast
- 26.13.1. Market Revenue, by Product (2019-2032)
- 26.13.2. Market Revenue, by Sample Type (2019-2032)
- 26.13.3. Market Revenue, by End User (2019-2032)
- 26.13.4. Market Revenue, by Drug Type (2019-2032)

Chapter 27. South Africa Market

27.1. Overview
27.2. Economic Indicators
27.3. Demographics and Population Insights
27.4. Regional Hotspots
27.5. Growth Drivers
27.6. Challenges and Barriers
27.7. Competitive Strategies
27.8. Emerging Players
27.9. Import/Export Policies
27.10. Compliance Requirements
27.11. Emerging Investment Areas
27.12. Major Ongoing Projects
27.13. Market Size and Forecast
- 27.13.1. Market Revenue, by Product (2019-2032)
- 27.13.2. Market Revenue, by Sample Type (2019-2032)
- 27.13.3. Market Revenue, by End User (2019-2032)
- 27.13.4. Market Revenue, by Drug Type (2019-2032)

Chapter 28. Saudi Arabia Market

28.1. Overview
28.2. Economic Indicators
28.3. Demographics and Population Insights
28.4. Regional Hotspots
28.5. Growth Drivers
28.6. Challenges and Barriers
28.7. Competitive Strategies
28.8. Emerging Players
28.9. Import/Export Policies
28.10. Compliance Requirements
28.11. Emerging Investment Areas
28.12. Major Ongoing Projects
28.13. Market Size and Forecast
- 28.13.1. Market Revenue, by Product (2019-2032)
- 28.13.2. Market Revenue, by Sample Type (2019-2032)
- 28.13.3. Market Revenue, by End User (2019-2032)
- 28.13.4. Market Revenue, by Drug Type (2019-2032)

Chapter 29. U.A.E. Market

29.1. Overview
29.2. Economic Indicators
29.3. Demographics and Population Insights
29.4. Regional Hotspots
29.5. Growth Drivers
29.6. Challenges and Barriers
29.7. Competitive Strategies
29.8. Emerging Players
29.9. Import/Export Policies
29.10. Compliance Requirements
29.11. Emerging Investment Areas
29.12. Major Ongoing Projects
29.13. Market Size and Forecast
- 29.13.1. Market Revenue, by Product (2019-2032)
- 29.13.2. Market Revenue, by Sample Type (2019-2032)
- 29.13.3. Market Revenue, by End User (2019-2032)
- 29.13.4. Market Revenue, by Drug Type (2019-2032)

Chapter 30. Company Profiles

Chapter 31. Appendix

31.1. Sources and References
31.2. Related Reports

Drug of Abuse Testing Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2025 - 2032)